Anti-PVRIG antibody, pharmaceutical composition and application thereof

CN118946588APending Publication Date: 2024-11-12BIOTHEUS INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380031274.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-02
Filing Date
2023-03-31
Publication Date
2024-11-12

Smart Images

  • Figure CN118946588A_ABST
    Figure CN118946588A_ABST
Patent Text Reader

Abstract

The invention provides an anti-PVRIG antibody or an antigen binding fragment thereof, the antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 to HCDR3, the light chain variable region comprises LCDR1 to LCDR3, the amino acid sequence of the heavy chain variable region of the antibody and the HCDR1 is as shown in SEQ ID NO: 9, the amino acid sequence of the HCDR2 is as shown in SEQ ID NO: 10, and the amino acid sequence of the HCDR3 is as shown in SEQ ID NO: 11. In the light chain variable region of the antibody, the amino acid sequence of the LCDR1 is shown as SEQ ID NO: 12, the amino acid sequence of the LCDR2 is shown as SEQ ID NO: 13, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO: 14.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-PVRIG antibodies, pharmaceutical compositions and uses thereof Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to an anti-PVRIG antibody, a pharmaceutical composition and use thereof. Background Art

[0002] The poliovirus receptor related immunoglobulin domain-containing protein (PVRIG, also known as CD112R) belongs to the PVR family. Its extracellular region has an IgV domain and its intracellular region contains an ITIM (Immunoreceptor tyrosine-based inhibitory motif) domain. It is a new type of immunosuppressive receptor expressed on natural killer (NK) cells and T cells.

[0003] PVRL2 (poliovirus receptor-related 2, CD112, Nectin-2) is an adhesion molecule involved in cell-cell junctions and is overexpressed in various cancers. PVRL2 has been identified as the only functional ligand for PVRIG, binding to PVRIG with high affinity to inhibit T and NK cell immune activation. PVRL2 is also a ligand for the coactivator receptor DNAX accessory molecule 1 (DNAM-1, CD226) and weakly binds to another inhibitory receptor, the T-cell immunoreceptor with Ig and ITIM domains (TIGIT). Therefore, similar to the immunosuppressive mechanism of TIGIT, a member of the same family, PVRIG can also exert an immunosuppressive effect by competing with CD226 for its ligand, PVRL2, thereby blocking the activation signal transmitted by CD226.

[0004] PVRIG or its ligand PVRL2 is highly expressed in lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer and their tumor microenvironment, and PVRIG is also highly expressed on NK cells of prostate cancer patients (Whelan S, et al. Cancer Immunol Res. 2019; 7(2): 257-268.). In addition, PVRIG is co-expressed with the exhausted CD8+ T cell marker TIGIT and PD-1 molecules, suggesting that PVRIG expression has certain tumor specificity and may be related to the activation / exhaustion state of TILs in the tumor (Whelan S, et al. Cancer Immunol Res. 2019; 7(2): 257-268.). WO2021180205A1 reports that anti-PVRIG antibodies can be used for the prevention and treatment of lung cancer, breast cancer, ovarian cancer, kidney cancer, gastric cancer, endometrial cancer, head and neck cancer, etc.

[0005] Studies in preclinical mouse tumor models have shown that PVRIG deficiency or blockade can restore T / NK cell activity and promote anti-tumor immune responses. CD8+ T cells isolated from Pmel-1TCR-CD112R-deficient mice exhibited enhanced degranulation and cytokine secretion. Compared with wild-type mice, the growth of MC38 tumors in CD112R-deficient mice was slowed, and CD8+ TILs exhibited enhanced immune responses and transcriptome signatures of upregulated inflammation / cytotoxicity-related genes. The literature also reported that the combination of PVRIG antibodies or PVRIG knockout mice with PD-L1 antibodies had better therapeutic effects than PD-L1 antibodies alone in MC38 and CT26 mouse tumor models (Murter B, et al. Cancer Immunology Research, 2019.). Feng Xu et al. demonstrated that blocking the interaction between PVRIG and CD112 with an antibody can enhance NK cell cytotoxicity against tumor cells. Furthermore, combining it with a TIGIT-blocking monoclonal antibody can further enhance the trastuzumab-mediated NK cell killing effect against breast cancer cells (Xu F, et al. Cancer Immunology Immunotherapy Cii, 2017). In a knockout mouse model, PVRIG antibodies can reduce tumor growth in TIGIT- / - mice, and tumor growth control in PVRIG and TIGIT double knockout mice is further improved compared to single knockout mice (RJ Sullivan, et al, ASCO-SITC Clinical Immuno-Oncology Symposium, 2020).

[0006] Preclinical data suggest that PVRIG antibodies can effectively stimulate anti-tumor immune responses in certain cancers and have been found to exhibit synergistic effects with PD-1 / L1 and TIGIT antibodies, enhancing T / NK cell function, improving anti-tumor responses, and slowing tumor growth. Using PVRIG as a therapeutic target has the potential to enhance the therapeutic efficacy of existing antibody drugs (such as anti-TIGIT and anti-PD-1 / L1 antibodies), presenting advantages over other drug targets and combination therapies currently under clinical scrutiny. COM701, developed by Compugen, is the world's first clinically approved PVRIG antibody and is currently undergoing a Phase I study in combination with a TIGIT monoclonal antibody (COM902). Compugen has also partnered with Bristol-Myers Squibb to conduct a Phase I triplet trial of COM701, BMS-986207, and nivolumab. Additionally, GSK4381562, licensed from Surface Oncology to GSK, and JS009, developed by Junshi Biosciences in China, have submitted clinical trial applications before the end of 2021. Amgen also has a PVRIG monoclonal antibody in the preclinical stage.

[0007] Therefore, there is a need in the art to develop new anti-PVRIG antibodies with high affinity, high selectivity and high biological activity for the treatment of diseases, especially cancer.

[0008] Summary of the Invention

[0009] Through in-depth research and creative work, the present inventors have developed novel anti-PVRIG antibodies. Surprisingly, the present inventors have discovered that the anti-PVRIG antibodies of the present invention possess excellent affinity and biological activity, and have anti-tumor potential. Consequently, the present inventors provide the following invention:

[0010] One aspect of the present invention relates to an anti-PVRIG antibody or an antigen-binding fragment thereof, wherein:

[0011] The antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein:

[0012] the heavy chain variable region of the antibody,

[0013] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 10, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 11,

[0014] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 15, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 16, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 17,

[0015] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 21, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 22, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 23, or

[0016] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 27, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 28, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 29;

[0017] and

[0018] the light chain variable region of the antibody,

[0019] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 13, and the amino acid sequence of LCDR1 is shown in SEQ ID NO: 14,

[0020] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 18, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 19, and the amino acid sequence of LCDR1 is shown in SEQ ID NO: 20,

[0021] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 24, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 25, and the amino acid sequence of LCDR1 is shown in SEQ ID NO: 26, or

[0022] The amino acid sequence of LCDR1 is shown in SEQ ID NO:30, the amino acid sequence of LCDR1 is shown in SEQ ID NO:31, and the amino acid sequence of LCDR1 is shown in SEQ ID NO:32.

[0023] In some embodiments of the present invention, the anti-PVRIG antibody or antigen-binding fragment thereof, wherein,

[0024] The amino acid sequence of HCDR1 is shown in SEQ ID NO:9, the amino acid sequence of HCDR2 is shown in SEQ ID NO:10, the amino acid sequence of HCDR3 is shown in SEQ ID NO:11, the amino acid sequence of LCDR1 is shown in SEQ ID NO:12, the amino acid sequence of LCDR2 is shown in SEQ ID NO:13, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:14;

[0025] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 15, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 16, the amino acid sequence of HCDR3 is shown in SEQ ID NO: 17, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 18, the amino acid sequence of LCDR2 is shown in SEQ ID NO: 19, and the amino acid sequence of LCDR3 is shown in SEQ ID NO: 20;

[0026] The amino acid sequence of HCDR1 is shown in SEQ ID NO:21, the amino acid sequence of HCDR2 is shown in SEQ ID NO:22, the amino acid sequence of HCDR3 is shown in SEQ ID NO:23, the amino acid sequence of LCDR1 is shown in SEQ ID NO:24, the amino acid sequence of LCDR2 is shown in SEQ ID NO:25, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:26;

[0027] or

[0028] The amino acid sequence of HCDR1 is shown in SEQ ID NO:27, the amino acid sequence of HCDR2 is shown in SEQ ID NO:28, the amino acid sequence of HCDR3 is shown in SEQ ID NO:29, the amino acid sequence of LCDR1 is shown in SEQ ID NO:30, the amino acid sequence of LCDR2 is shown in SEQ ID NO:31, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:32.

[0029] The variable regions of the light chain and heavy chain determine the binding of the antigen; the variable region of each chain contains three hypervariable regions, called complementarity determining regions (CDRs) (the CDRs of the heavy chain (H) include HCDR1, HCDR2, and HCDR3, and the CDRs of the light chain (L) include LCDR1, LCDR2, and LCDR3. In some embodiments of the present invention, HCDR1-HCDR3 and LCDR1-LCDR3 are defined or numbered with reference to U.S. Patent Publication US20210380669A1 or the literature Lu. et al (Deamidation and isomerization liability analysis of 131 clinical-stage antibodies, MABS, 2019, VOL.11, NO.1, 45–57, DOI: 10.1080 / 19420862.2018.1548233).

[0030] In some embodiments of the present invention, the anti-PVRIG antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is selected from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7;

[0031] and

[0032] The amino acid sequence of the light chain variable region is selected from SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO: 8.

[0033] In some embodiments of the present invention, the anti-PVRIG antibody or antigen-binding fragment thereof, wherein,

[0034] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 2;

[0035] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 3, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 4;

[0036] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 5, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 6;

[0037] or

[0038] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8.

[0039] In some embodiments of the present invention, the anti-PVRIG antibody or antigen-binding fragment thereof, wherein the heavy chain constant region of the antibody is Ig gamma-1 chain C region or Ig gamma-4 chain C region; the light chain constant region is Ig kappa chain C region;

[0040] Preferably, the amino acid sequence of the heavy chain constant region of the antibody is shown as SEQ ID NO: 33, SEQ ID NO: 34 or SEQ ID NO: 35, and the amino acid sequence of the light chain constant region of the antibody is shown as SEQ ID NO: 36.

[0041] In some embodiments of the present invention, the anti-PVRIG antibody or antigen-binding fragment thereof comprises an L234A mutation and an L235A mutation (abbreviated as LALA) in the heavy chain constant region of the antibody according to the EU numbering system. In the present invention, unless otherwise specified, the letter before the position represents the amino acid before the mutation, and the letter after the position represents the amino acid after the mutation.

[0042] In some embodiments of the present invention, the anti-PVRIG antibody or its antigen-binding fragment, wherein the anti-PVRIG antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single-chain antibody, humanized antibody, chimeric antibody or diabody.

[0043] In some embodiments of the present invention, the anti-TIGIT antibody or antigen-binding fragment thereof, wherein,

[0044] The antibodies include non-CDR regions, and the non-CDR regions are from a species other than murine, such as a human antibody.

[0045] In some embodiments of the present invention, the anti-PVRIG antibody or antigen-binding fragment thereof, wherein the EC binding of the antibody to the human PVRIG protein overexpressed on the surface of CHO cells 50 Less than 3 nM, less than 2.9 nM or less than 2.8 nM; preferably, the EC 50 Measured by flow cytometry.

[0046] Another aspect of the present invention relates to an isolated nucleic acid molecule encoding the anti-TIGIT antibody or antigen-binding fragment thereof according to any one of the present invention.

[0047] Yet another aspect of the present invention relates to a recombinant vector comprising the isolated nucleic acid molecule of the present invention.

[0048] Another aspect of the present invention relates to a host cell comprising the isolated nucleic acid molecule of the present invention or the recombinant vector of the present invention.

[0049] Another aspect of the present invention relates to a conjugate comprising an antibody and a conjugated moiety, wherein the antibody is an anti-PVRIG antibody or antigen-binding fragment thereof according to any one of the present invention, and the conjugated moiety is a detectable label; preferably, the conjugated moiety is a radioactive isotope, a fluorescent substance, a colored substance or an enzyme.

[0050] Another aspect of the present invention relates to a kit comprising the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of the present invention, or the conjugate of the present invention;

[0051] Preferably, the kit further comprises a second antibody that specifically recognizes the antibody; optionally, the second antibody further comprises a detectable label, such as a radioisotope, a fluorescent substance, a colored substance or an enzyme.

[0052] Another aspect of the present invention relates to a pharmaceutical composition comprising the anti-PVRIG antibody or antigen-binding fragment thereof or the conjugate of the present invention as described in any one of the present invention; optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0053] In some embodiments of the present invention, the pharmaceutical composition further comprises one or more anti-TIGIT antibodies;

[0054] Preferably, the pharmaceutical composition further comprises one or more anti-PD-1 antibodies or one or more anti-PD-L1 antibodies.

[0055] In some embodiments of the present invention, the pharmaceutical composition, wherein

[0056] The molar ratio of the anti-PVRIG antibody or antigen-binding fragment thereof to the anti-TIGIT antibody is (1:5)-(5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1;

[0057] and / or

[0058] The molar ratio of the anti-PVRIG antibody or its antigen-binding fragment to the anti-PD-1 antibody or anti-PD-L1 antibody is (1:5)-(5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1.

[0059] In one or more embodiments of the present invention, the pharmaceutical composition, wherein the anti-TIGIT antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein:

[0060] The amino acid sequence of HCDR1 is shown in SEQ ID NO:42, the amino acid sequence of HCDR2 is shown in SEQ ID NO:43, the amino acid sequence of HCDR3 is shown in SEQ ID NO:44, the amino acid sequence of LCDR1 is shown in SEQ ID NO:45, the amino acid sequence of LCDR2 is shown in SEQ ID NO:46, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:47;

[0061] Preferably, the amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO:40, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:41.

[0062] In one or more embodiments of the present invention, the pharmaceutical composition, wherein the anti-PD-1 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein:

[0063] The amino acid sequence of HCDR1 is shown in SEQ ID NO:50, the amino acid sequence of HCDR2 is shown in SEQ ID NO:51, the amino acid sequence of HCDR3 is shown in SEQ ID NO:52, the amino acid sequence of LCDR1 is shown in SEQ ID NO:53, the amino acid sequence of LCDR2 is shown in SEQ ID NO:54, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:55;

[0064] Preferably, the amino acid sequence of the heavy chain variable region of the anti-PD-1 antibody is shown in SEQ ID NO: 48, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 49.

[0065] In one or more embodiments of the present invention, the pharmaceutical composition, wherein the unit dose of the pharmaceutical composition, calculated according to the mass of the anti-PVRIG antibody or antigen-binding fragment thereof, is 100 mg-1000 mg, 200 mg-800 mg, 200 mg-500 mg, 300 mg-600 mg, 400 mg-500 mg or 450 mg.

[0066] In some embodiments of the present invention, the active ingredient of the pharmaceutical composition consists of an anti-PVRIG antibody or an antigen-binding fragment thereof.

[0067] In some embodiments of the present invention, the active ingredients of the pharmaceutical composition are composed of anti-PVRIG antibodies or antigen-binding fragments thereof and anti-TIGIT antibodies.

[0068] In some embodiments of the present invention, the active ingredients of the pharmaceutical composition are composed of anti-PVRIG antibody or its antigen-binding fragment, anti-TIGIT antibody and anti-PD-1 antibody.

[0069] Another aspect of the present invention relates to a combination product comprising a first product and a second product in separate packages, wherein:

[0070] The first product comprises the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of the present invention or the conjugate according to the present invention;

[0071] The second product comprises at least one anti-TIGIT antibody;

[0072] Preferably, the combination product further comprises a third product comprising at least one anti-PD-1 antibody or at least one anti-PD-L1 antibody;

[0073] Preferably, the first product, the second product and the third product further independently contain one or more pharmaceutically acceptable excipients;

[0074] Preferably, the combination product further comprises product instructions.

[0075] In some embodiments of the present invention, the combination product, wherein,

[0076] The molar ratio of the anti-PVRIG antibody or antigen-binding fragment thereof to the anti-TIGIT antibody is (1:5)-(5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1;

[0077] and / or

[0078] The molar ratio of the anti-PVRIG antibody or its antigen-binding fragment to the anti-PD-1 antibody or anti-PD-L1 antibody is (1:5)-(5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1.

[0079] In some embodiments of the present invention, the combination product, wherein the anti-TIGIT antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein:

[0080] The amino acid sequence of HCDR1 is shown in SEQ ID NO:42, the amino acid sequence of HCDR2 is shown in SEQ ID NO:43, the amino acid sequence of HCDR3 is shown in SEQ ID NO:44, the amino acid sequence of LCDR1 is shown in SEQ ID NO:45, the amino acid sequence of LCDR2 is shown in SEQ ID NO:46, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:47;

[0081] Preferably, the amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO:40, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:41.

[0082] In some embodiments of the present invention, the combination product, wherein the anti-PD-1 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein:

[0083] The amino acid sequence of HCDR1 is shown in SEQ ID NO:50, the amino acid sequence of HCDR2 is shown in SEQ ID NO:51, the amino acid sequence of HCDR3 is shown in SEQ ID NO:52, the amino acid sequence of LCDR1 is shown in SEQ ID NO:53, the amino acid sequence of LCDR2 is shown in SEQ ID NO:54, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:55;

[0084] Preferably, the amino acid sequence of the heavy chain variable region of the anti-PD-1 antibody is shown in SEQ ID NO: 48, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 49.

[0085] Another aspect of the present invention relates to use of the antibody or antigen-binding fragment thereof, the conjugate, or the pharmaceutical composition of any one of the present invention in the preparation of a medicament for treating or preventing tumors.

[0086] Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer;

[0087] Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.

[0088] The antibody or antigen-binding fragment thereof according to any one of the present invention, the conjugate according to the present invention, or the pharmaceutical composition according to any one of the present invention, for treating or preventing tumors;

[0089] Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer;

[0090] Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.

[0091] Another aspect of the present invention relates to a method for treating or preventing tumors, comprising the steps of administering to a subject in need thereof an effective amount of the antibody or antigen-binding fragment thereof, the conjugate, or the pharmaceutical composition of any one of the present invention;

[0092] Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer;

[0093] Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.

[0094] In one or more embodiments of the present invention, the method, wherein,

[0095] The single dose of the anti-PVRIG antibody is 0.1-100 mg per kilogram of body weight, preferably 1-10 mg (e.g., 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg or 10 mg); alternatively, the single dose of the anti-PVRIG antibody is 10-1000 mg per subject (e.g., about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg or about 1000 mg), preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg or 200 mg;

[0096] Preferably, the drug is administered once every 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks or 3 weeks;

[0097] Preferably, the administration is by intravenous drip or intravenous injection.

[0098] In some embodiments, the anti-PVRIG antibody is administered in a 2-week (14-day) or 3-week (21-day) cycle, preferably intravenously on the first day (D1) of each cycle. For example, the anti-PVRIG antibody is administered once every two weeks (q2w) or once every three weeks (q3w).

[0099] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures for cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.

[0100] As used herein, reference to the amino acid sequence of PVRIG (NCBI GenBank ID: NP_076975.2) includes the full-length or extracellular fragments of the PVRIG protein; it also includes PVRIG fusion proteins, such as fragments fused to the Fc protein fragment of mouse or human IgG (mFc or hFc). However, those skilled in the art will appreciate that mutations or variations (including but not limited to substitutions, deletions, and / or additions) can occur naturally or be artificially introduced into the amino acid sequence of the PVRIG protein without affecting its biological function. Therefore, in the present invention, the term "PVRIG protein" or "PVRIG" should include all such sequences, including the sequence shown and its natural or artificial variants. Furthermore, when describing a sequence fragment of the PVRIG protein, it includes not only the sequence fragment, but also the corresponding sequence fragments in its natural or artificial variants.

[0101] As used herein, when referring to the amino acid sequence of TIGIT (NCBI GenBank ID: NP_776160.2), it includes the full length or functional fragments of the TIGIT protein; it also includes fusion proteins of TIGIT, such as fragments fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, those skilled in the art understand that mutations or variations (including but not limited to substitutions, deletions and / or additions) can be naturally generated or artificially introduced into the amino acid sequence of the TIGIT protein without affecting its biological function. Therefore, in the present invention, the term "TIGIT protein" or "TIGIT" should include all such sequences, including the sequence shown and its natural or artificial variants. Furthermore, when describing a sequence fragment of the TIGIT protein, it includes not only the sequence fragment, but also the corresponding sequence fragments in its natural or artificial variants.

[0102] As used herein, the term EC 50 It refers to the concentration for 50% of maximal effect, which is the concentration that can cause 50% of the maximum effect.

[0103] As used herein, the term "antibody" refers to an immunoglobulin molecule typically composed of two pairs of polypeptide chains, each pair having one "light" (L) chain and one "heavy" (H) chain. Antibody light chains can be classified as kappa and lambda light chains. Heavy chains can be classified as μ, δ, γ, α, or ε, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (V H ) and heavy chain constant region (C H ). The heavy chain constant region consists of three domains (C H1 、C H2 and C H3 Each light chain consists of a light chain variable region (V L ) and the light chain constant region (C L ). The light chain constant region consists of a domain C L The constant region of the antibody mediates the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. H and V L The V domains can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L It consists of three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable region (V H and V L) form antigen-binding sites, respectively. The assignment of amino acids to each region or domain follows the Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda Md (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 1987; 196: 901-917; Chothia et al. Nature 1989; 342: 878-883 or the IMGT numbering system, as defined by Ehrenmann, Francois, Quentin Kaas, and Marie-Paule Lefranc. "IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF." Nucleic acids research 2009; 38(suppl_1): D301-D307. The term "antibody" is not limited to any particular method for producing the antibody. For example, it includes, in particular, recombinant antibodies, monoclonal antibodies and polyclonal antibodies.The antibody can be an antibody of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibody.

[0104] As used herein, the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody is bound, and / or competes with the full-length antibody for specific binding to the antigen, and is also referred to as an "antigen-binding portion". See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of an antibody can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of an intact antibody. In some cases, antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementary determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, and polypeptides comprising at least a portion of an antibody sufficient to confer specific antigen-binding ability to a polypeptide.

[0105] As used herein, the term "Fd fragment" means a fragment consisting of H and C H The term "Fv fragment" refers to an antibody fragment consisting of a V domain of a single arm of an antibody. L and V H The term "dAb fragment" refers to an antibody fragment consisting of a V H domains (Ward et al., Nature 341:544-546 (1989)); the term "Fab fragment" means an antibody fragment consisting of V L 、V H 、C L and C H The term "F(ab')2 fragment" refers to an antibody fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.

[0106] In some cases, the antigen-binding fragment of an antibody is a single-chain antibody (e.g., scFv), in which V L and V H The domains are paired to form monovalent molecules through linkers that enable them to be produced as a single polypeptide chain (see, e.g., Bird et al., Science 242:423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)). Such scFv molecules can have the general structure: NH2-V L -Connector-V H -COOH or NH2-V H -Connector-V L -COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof. For example, a linker having the amino acid sequence (GGGGS)4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448). Other linkers that can be used in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.

[0107] In some cases, the antigen-binding fragment of an antibody is a diabody, i.e., a bivalent antibody in which VH and V L The domains are expressed on a single polypeptide chain, but with a linker that is too short to allow pairing between the two domains on the same chain, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak RJ et al., Structure 2:1121-1123 (1994)).

[0108] In other cases, the antigen-binding fragment of an antibody is a "bispecific antibody", which refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) or an antibody analog through a coupling arm, and the coupling method includes but is not limited to chemical reaction, gene fusion and enzymatic reaction. The antigen-binding fragment of an antibody can be a "multispecific antibody" including, for example: a trispecific antibody and a tetraspecific antibody, the former being an antibody with three different antigen-binding specificities, and the latter being an antibody with four different antigen-binding specificities. For example, a designed ankyrin repeat protein (DARPin) is linked to an IgG antibody, a scFv-Fc antibody fragment, or a combination thereof, such as CN104341529A. The anti-IL-17a fynomer is bound to an anti-IL-6R antibody, such as WO2015141862A1.

[0109] Antigen-binding fragments of antibodies (e.g., the above-mentioned antibody fragments) can be obtained from a given antibody (e.g., monoclonal antibodies ADI-56127, ADI-56204, ADI-56249 and ADI-56145 provided herein) using conventional techniques known to those skilled in the art (e.g., recombinant DNA technology or enzymatic or chemical cleavage methods), and the antigen-binding fragments of antibodies can be screened for specificity in the same manner as for intact antibodies.

[0110] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" refer to an antibody or an antibody fragment from a group of highly homologous antibody molecules, that is, a group of identical antibody molecules except for possible spontaneous natural mutations. Monoclonal antibodies have high specificity for a single epitope on an antigen. Polyclonal antibodies are relative to monoclonal antibodies and usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen. Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. ( G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. Nature, 1975; 256 (5517): 495), but it can also be obtained by using recombinant DNA technology (see, for example, US Patent 4,816,567).

[0111] As used herein, the term "humanized antibody" refers to an antibody or antibody fragment obtained by replacing all or part of the CDR region of a human immunoglobulin (recipient antibody) with the CDR region of a non-human antibody (donor antibody), wherein the donor antibody can be a non-human (e.g., mouse, rat, or rabbit) antibody with the desired specificity, affinity, or reactivity. In addition, some amino acid residues in the framework region (FR) of the recipient antibody can also be replaced with amino acid residues of the corresponding non-human antibody, or with amino acid residues of other antibodies, to further improve or optimize the performance of the antibody. For more details on humanized antibodies, see, for example, Jones et al., Nature 1986; 321: 522-525; Reichmann et al., Nature 1988; 332: 323-329; Presta, Curr. Op. Struct. Biol., 1992; 2: 593-596; and Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? [J]. Immunol. Today, 2000; 21(8): 397-402.

[0112] As used herein, the term "isolated" or "isolated" refers to something that is obtained artificially from its natural state. If a substance or component is "isolated" in nature, it may be that its natural environment has been changed, or that the substance has been separated from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and a highly pure identical polynucleotide or polypeptide isolated from this natural state is called isolated. The term "isolated" or "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.

[0113] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain an origin of replication.

[0114] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, GS cells, BHK cells, HEK 293 cells or human cells.

[0115] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" have the same meaning and are used interchangeably; the terms "polyclonal antibody" and "polyclonal antibody" have the same meaning and are used interchangeably; the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Furthermore, in the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0116] As used herein, the term "pharmaceutically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, pH adjusters include, but are not limited to, phosphate buffers; surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80; and ionic strength enhancers include, but are not limited to, sodium chloride.

[0117] As used herein, the term "effective amount" refers to an amount sufficient to achieve or at least partially achieve a desired effect. For example, an effective amount for preventing a disease (e.g., a tumor) refers to an amount sufficient to prevent, inhibit, or delay the occurrence of a disease (e.g., a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially inhibit the disease and its complications in a patient already suffering from the disease.

[0118] As used herein, the terms "hybridoma" and "hybridoma cell line" are used interchangeably, and the terms "hybridoma" and "hybridoma cell line" also include subclones and progeny cells of the hybridoma when referring to them.

[0119] In the present invention, unless otherwise specified, the "first" (e.g., the first product), "second" (e.g., the second product), and "third" (e.g., the third product) are for the purpose of distinguishing references or clarifying expressions, and do not have a typical order meaning.

[0120] Advantageous Effects of the Invention

[0121] The present invention achieves one or more of the following technical effects (1) to (4):

[0122] (1) The antibodies of the present invention can bind to PVRIG with high affinity.

[0123] (2) The antibody of the present invention is likely to have a synergistic effect with an anti-TIGIT antibody, an anti-PD-1 antibody, or an anti-PD-L1 antibody.

[0124] (3) The antibodies of the present invention can effectively treat and / or prevent tumors, such as colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumors, urothelial cancer, bone tumors, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumors, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer, etc.

[0125] (4) The antibodies of the present invention have lower toxic side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0126] Figures 1A to 1B: Binding curves of anti-PVRIG antibodies to human PVRIG overexpressed in CHO cells.

[0127] 2A to 2B : Binding curves of anti-PVRIG antibodies to cynomolgus monkey PVRIG overexpressed on CHO cells.

[0128] 3A to 3B : Binding curves of anti-PVRIG antibodies to mouse PVRIG overexpressed on CHO cells.

[0129] 4A to 4B are graphs showing that anti-PVRIG antibodies block the binding of human PVRIG to human CD112 overexpressed on CHO cells.

[0130] 5A to 5B are graphs showing that anti-PVRIG antibodies block the binding of mouse CD112 to mouse PVRIG protein.

[0131] FIG6 : Binding curve of anti-PVRIG antibody to PVRIG on activated human primary T cells.

[0132] Figure 7: Curve graph of the combined blocking of PVRIG / CD112 and TIGIT / CD155 signaling pathways by anti-PVRIG antibodies and anti-TIGIT antibodies.

[0133] Figure 8: Curve graph of the combined blocking of PVRIG / CD112, TIGIT / CD155 and PD-1 / PD-L1 signaling pathways by anti-PVRIG antibodies in combination with anti-TIGIT and anti-PD-L1 antibodies.

[0134] Figures 9A to 9C show the results of ADCC experiments in CHO cells overexpressing human PVRIG, overexpressing cynomolgus monkey PVRIG, and overexpressing mouse PVRIG mediated by anti-PVRIG antibodies, respectively.

[0135] Figure 10: Pharmacological efficacy of anti-PVRIG antibody in wild-type mouse CT-26 tumor model.

[0136] Figure 11: Pharmacodynamics of anti-PVRIG antibody in NDG mouse model inoculated with A375 and human PBMCs.

[0137] Figure 12: Pharmacological efficacy of anti-PVRIG antibody combined with anti-TIGIT antibody in the NDG mouse model inoculated with mixed A375 and human PBMCs.

[0138] Figure 13: Pharmacological efficacy of anti-PVRIG antibody combined with anti-TIGIT and anti-PD-1 antibodies in the NDG mouse model inoculated with A375 and human PBMCs.

[0139] Figure 14: Half-life curve of anti-PVRIG antibody in mice. DETAILED DESCRIPTION

[0140] The embodiments of the present invention will be described in detail below with reference to the examples, but it will be understood by those skilled in the art that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be obtained commercially.

[0141] Antibody Atezolizumab (ATE): anti-PD-L1 monoclonal antibody, trade name Tecentriq, Roche.

[0142] The following control antibodies used in the examples were expressed and purified from HEK293 cells:

[0143] COM701 is an anti-human PVRIG antibody from Compugen, expressed in HEK293 cells. Its light chain variable region sequence and heavy chain variable region sequence are consistent with SEQ ID NO: 1372 and SEQ ID NO: 1380 in U.S. Patent No. 10227408B2.

[0144] Mab46 is an anti-human PVRIG antibody from Surface Oncology expressed in HEK293 cells. The sequences of its light chain variable region and heavy chain variable region are consistent with SEQ ID NO: 912 and SEQ ID NO: 918 in U.S. Patent Publication No. US20200040081A1.

[0145] Tiragolumab is an anti-human TIGIT antibody from Genentech expressed in HEK293 cells. Its light and heavy chain sequences are derived from WHO Drug Information, Vol. 31, No. 2, 2017, Proposed INN: List 117, CAS No.: 1918185-84-8.

[0146] Example 1: Sequence design, expression and purification of antibodies

[0147] 1. Antibody Sequence Design

[0148] Based on the yeast antibody display library (Adimab), amplification and optimization were performed according to existing methods (see patent applications WO2009036379, WO2010105256, and WO2012009568). The yeast cells obtained by screening were shaken and induced at 30°C for 48 hours to secrete and express the target anti-PVRIG antibody (full-length IgG). After induction, the yeast cells were removed by centrifugation at 1300 rpm for 10 minutes, and the supernatant was harvested. The anti-PVRIG antibodies in the supernatant were purified using Protein A, eluted with pH 2.0 acetic acid solution, and the anti-PVRIG antibodies were harvested. Among them, the anti-PVRIG antibodies ADI-56127, ADI-56204, ADI-56249, and ADI-56145 were obtained. Meanwhile, antibodies ADI-56127, ADI-56204, ADI-56249, and ADI-56145 were cleaved with papain and purified with KappaSelect (GE Life Sciences) to obtain the corresponding antibody Fab fragments.

[0149] The variable region sequence information of the four antibodies ADI-56127, ADI-56204, ADI-56249, and ADI-56145 is as follows.

[0150] Heavy chain variable region of ADI-56127:

[0151] Light chain variable region of ADI-56127:

[0152] Heavy chain variable region of ADI-56204:

[0153] Light chain variable region of ADI-56204:

[0154] Heavy chain variable region of ADI-56249:

[0155] Light chain variable region of ADI-56249:

[0156] Heavy chain variable region of ADI-56145:

[0157] Light chain variable region of ADI-56145:

[0158] The CDRs of the above antibodies are as follows: <h2 style=";text-align:left;direction:ltr">

[0159] <h2 style=";text-align:left;direction:ltr"> (1)ADI-56127<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0160] <h2 style=";text-align:left;direction:ltr"> HCDR1:GTESVDAIS(SEQ ID NO:9)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0161] <h2 style=";text-align:left;direction:ltr"> HCDR2:DIIPFFDTDYAQKFQG(SEQ ID NO:10)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0162] <h2 style=";text-align:left;direction:ltr"> HCDR3:AREGGTSWTHFFDL(SEQ ID NO:11)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0163] <h2 style=";text-align:left;direction:ltr"> LCDR1:RASQSVSSSYLA(SEQ ID NO:12)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0164] <h2 style=";text-align:left;direction:ltr"> LCDR2: GASSRAT(SEQ ID NO: 13)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0165] <h2 style=";text-align:left;direction:ltr"> LCDR3:QQYGSSPIT(SEQ ID NO:14)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0166] <h2 style=";text-align:left;direction:ltr"> (2) ADI-56204<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0167] <h2 style=";text-align:left;direction:ltr"> HCDR1:YTFTHYGIY(SEQ ID NO:15)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0168] <h2 style=";text-align:left;direction:ltr"> HCDR2:HIYAYSGDTDYAQKLQG(SEQ ID NO:16)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0169] <h2 style=";text-align:left;direction:ltr"> HCDR3:ARGSPTYEHFNWFDP(SEQ ID NO:17)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0170] <h2 style=";text-align:left;direction:ltr"> LCDR1:QASDDISDYLN(SEQ ID NO:18)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0171] <h2 style=";text-align:left;direction:ltr"> LCDR2: DASSLHT(SEQ ID NO:19)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0172] <h2 style=";text-align:left;direction:ltr"> LCDR3:QQYGNLPIT(SEQ ID NO:20)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0173] <h2 style=";text-align:left;direction:ltr"> (3) ADI-56249<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0174] <h2 style=";text-align:left;direction:ltr"> HCDR1:GTFSTFAIS(SEQ ID NO:21)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0175] <h2 style=";text-align:left;direction:ltr"> HCDR2:DIIPIFGSNYAQKFQG(SEQ ID NO:22)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0176] <h2 style=";text-align:left;direction:ltr"> HCDR3:ARGPLEGKVSPFDI(SEQ ID NO:23)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0177] LCDR1:RSSQSLLHSTGYNYLD(SEQ ID NO:24)

[0178] LCDR2: VGSTRAS (SEQ ID NO: 25)

[0179] LCDR3:MQERQFPIT(SEQ ID NO:26)

[0180] (4)ADI-56145

[0181] HCDR1:YTFTSYGIS(SEQ ID NO:27)

[0182] HCDR2: WISSYDASTKYSQELQG(SEQ ID NO:28)

[0183] HCDR3:ARGSPIYEHFNWFDP(SEQ ID NO:29)

[0184] LCDR1:RASQSVSSYLA(SEQ ID NO:30)

[0185] LCDR2:DSSNRAT (SEQ ID NO:31)

[0186] LCDR3: QQLSHHPLT(SEQ ID NO:32)

[0187] 1.2 Expression and purification of antibodies and their variants

[0188] For antibodies ADI-56127, ADI-56204, and the control antibody Mab46, their heavy chain variable regions (VH) were recombined into a wild-type human IgG1 heavy chain constant region (amino acid sequence shown in SEQ ID NO: 33). Furthermore, for antibodies ADI-56127, ADI-56204, ADI-56249, ADI-56145, and the control antibody Mab46, their heavy chain variable regions (VH) were recombined into a heavy chain constant region modified with L234A and L235A (amino acid sequence shown in SEQ ID NO: 34), forming a complete "VH-CH1-CH2-CH3" antibody heavy chain. For the control antibody COM701, its heavy chain variable region was recombined into a human IgG4 heavy chain constant region (amino acid sequence shown in SEQ ID NO: 35). Furthermore, the light chain variable regions (VL) of the above antibodies were recombined into a human kappa light chain constant region (amino acid sequence shown in SEQ ID NO: 36). Transient expression and purification were performed using the HEK293 expression system. The specific procedures were as follows: The pcDNA3.1 vector carrying the antibody heavy and light chains was chemically transfected into HEK293 cells and cultured at 37°C, 8% CO2 for 7 days. The cell fluid was collected and centrifuged at 13,000 rpm for 20 minutes. The supernatant was collected and purified by Protein A. The antibody purity was tested by SEC, and the endotoxin content was also controlled. The resulting antibodies were named ADI-56127-G1, ADI-56127-G1LALA, ADI-56204-G1, ADI-56204-G1LALA, ADI-56249-G1LALA, ADI-56145-G1LALA, Mab46-G1, Mab46-G1LALA, and COM701-G4.

[0189] Wild-type human IgG1 heavy chain constant region:

[0190] Heavy chain constant region modified by L234A and L235A:

[0191] Human IgG4 heavy chain constant region:

[0192] Human kappa light chain constant region:

[0193] Example 2: Antibody affinity detection

[0194] The biofilm optical interferometry technique (ForteBio) was used to determine the binding dissociation constant (K) of the antibody and its variants or Fab fragments obtained in Example 1 with human, cynomolgus monkey, and mouse PVRIG. DThe Fortebio affinity assay was performed according to the existing method (Este, P et al. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs, 2013. 5(2): p. 270-8). The amino acid sequences of the extracellular segments of human, cynomolgus monkey, and mouse PVRIG are shown in SEQ ID NOs: 37-39, respectively.

[0195] Human PVRIG extracellular domain amino acid sequence:

[0196] Amino acid sequence of the extracellular domain of cynomolgus monkey PVRIG:

[0197] Mouse PVRIG extracellular domain amino acid sequence:

[0198] The monovalent affinity of intact antibodies (i.e., full-length IgG obtained by Adimab) for the human PVRIG-his protein was measured by equilibrating the sensor offline in assay buffer for 20 minutes, followed by online measurement for 120 seconds to establish a baseline. The intact PVRIG antibody was then loaded onto the AHQ sensor to a thickness of 1 nm for affinity measurement. The loaded sensor was incubated with 100 nM PVRIG-his antigen until plateau, and then the sensor was transferred to assay buffer for at least 2 minutes for off-rate measurement. Kinetic analysis was performed using a 1:1 binding model.

[0199] The monovalent affinity of candidate antibody Fab fragments (i.e., Fab fragments derived from full-length IgG treated with papain) for human, cynomolgus monkey, and mouse PVRIG-Fc proteins was measured: the sensor was equilibrated offline in assay buffer for 20 minutes, followed by 120 seconds of online measurement to establish a baseline. The PVRIG-Fc antigen was then loaded onto the AHQ sensor to a thickness of 1 nm for affinity measurement. The loaded sensor was incubated with 100 nM Fab solution until plateau, and then the sensor was transferred to assay buffer for at least 2 minutes for dissociation rate measurement. Kinetic analysis was performed using a 1:1 binding model.

[0200] To measure the bivalent affinity of intact antibodies for cynomolgus monkey and mouse PVRIG-Fc proteins, the sensor was equilibrated offline in assay buffer for 20 minutes, followed by an online assay for 120 seconds to establish a baseline. The intact PVRIG antibody was then loaded onto the AHQ sensor to a thickness of 1 nm for affinity measurement. The loaded sensor was then incubated with a high concentration of an irrelevant intact antibody for 10 minutes to saturate the Fc binding sites on the AHQ sensor. The blocked sensor was then incubated with 100 nM PVRIG-Fc antigen until plateau phase, and the sensor was then transferred to assay buffer for at least 2 minutes for dissociation rate measurement. Kinetic analysis was performed using a 1:1 binding model.

[0201] In the above determination method, the K of the candidate molecule and its variant molecules D The values ​​are shown in Table 1 below.

[0202] Table 1: K values ​​of anti-PVRIG candidate molecules and their variants D value Note: "NB": no binding; "NA": not available.

[0203] From the results in Table 1 we can see that:

[0204] ADI-56127 and ADI-56249 have cross-binding activity with mouse PVRIG.

[0205] Example 3: Binding and blocking activity of anti-PVRIG antibodies against CHO cells overexpressing human / cynomolgus monkey / mouse PVRIG

[0206] 3.1 Flow cytometry was used to detect the binding activity of anti-PVRIG antibodies and their variants to human / cynomolgus monkey / mouse PVRIG overexpressed in CHO cells.

[0207] Specifically, CHO cells overexpressing human PVRIG (CHO-huPVRIG cells), CHO cells overexpressing crab-eating macaque PVRIG (CHO-cynoPVRIG cells), and CHO cells overexpressing mouse PVRIG (CHO-muPVRIG cells) were produced by pressure screening by transfecting the pCHO1.0 vector (purchased from Invitrogen) of human PVRIG, cynomolgus macaque PVRIG, and mouse PVRIG cDNA cloned into MCS. The expanded overexpressing cells were adjusted to an appropriate cell density and added to a 96-well flow plate. After centrifugation, the gradient diluted sample to be tested was added and incubated at 4°C for 30 minutes. Wash twice with PBS, add the corresponding fluorescent secondary antibody diluted to the appropriate concentration, incubate at 4°C for 30 minutes, and wash twice with PBS. Resuspend the cells in PBS, detect on a CytoFlex flow cytometer, and calculate the corresponding MFI. Graphpad software was used for graphical analysis to obtain EC 50 The results are shown in Table 2, Figures 1A to 1B, Figures 2A to 2B, and Figures 3A to 3B.

[0208] 3.2 Flow cytometry-based detection was used to detect the activity of anti-PVRIG antibodies and their variants in blocking the binding of human PVRIG to human CD112 overexpressed on CHO cells.

[0209] Specifically, CHO cells overexpressing human CD112 (CHO-huCD112 cells) were generated by pressure screening by transfecting the pCHO1.0 vector (purchased from Invitrogen) containing human CD112 cDNA cloned into MCS. The cell density of CHO-huCD112 cells was adjusted to 2×10 6 100 μL / well of the purified monoclonal antibody was added to a 96-well flow cytometer, centrifuged, and then used. Serial dilutions of the purified monoclonal antibody were performed with PBS. 60 μL / well of the diluted sample was added to a blank 96-well flow cytometer. Then, 1 μg / mL of human PVRIG protein with a mouse IgG2a Fc tag was added at 60 μL / well. Mix well and incubate at 4°C for 30 minutes. 100 μL / well of the incubated sample was added to a 96-well flow cytometer containing CHO-huCD112 cells. The plates were incubated at 4°C for 30 minutes and washed twice with PBS. 100 μL / well of APC goat anti-mouse IgG antibody diluted 100-fold in PBS was added. The plates were incubated at 4°C for 30 minutes and washed twice with PBS. The cells were resuspended in 100 μL / well of PBS and analyzed on a CytoFlex flow cytometer, and the corresponding MFI was calculated. The results are shown in Table 2 and Figures 4A and 4B.

[0210] 3.3 ELISA-based detection of anti-PVRIG antibodies and their variants to block the binding activity of mouse PVRIG protein to mouse CD112 protein.

[0211] Specifically, dilute the mouse CD112-his protein with 1× coating buffer to a final concentration of 1μg / mL, add 100μL / well to the ELISA plate, cover the plate, and incubate at 4°C overnight. Discard the coating solution in the ELISA plate, wash three times with 1× PBST, add 5% BSA / PBS at 200μL / well and block at room temperature for 2 hours. During the blocking period, take the sample to be tested and dilute it with 1% BSA / PBS in a gradient manner to a final volume of 60μL / well. Take the biotinylated Mouse PVRIG huFc protein and dilute it with 1% BSA / PBS to 2μg / mL, add 60μL / well to the above sample wells, mix well, and incubate at room temperature for 1 hour. Discard the blocking solution in the ELISA plate, add the above sample mixture at 100μL / well, and incubate at room temperature for 2 hours. The co-incubated samples were discarded, and the cells were washed three times with 1× PBST. 100 μL / well of SA-HRP diluted in 1% BSA / PBS was added and incubated at room temperature for 1 hour. The SA-HRP diluent was discarded, and the cells were washed three times with 1× PBST. 100 μL / well of ELISA developer was added and incubated at room temperature for 1-3 minutes. 50 μL / well of ELISA stop buffer was added, and the absorbance at 450 nm was read. Binding curves of concentration and absorbance were generated using GraphPad software. The results are shown in Table 2 and Figures 5A and 5B.

[0212] Table 2: Summary of cell binding blocking activity of overexpressed anti-PVRIG candidate molecules and their variants Note: "NB": no binding; "NA": not available.

[0213] The following conclusions can be drawn from Table 2, Figures 1A-1B, 2A-2B, and 3A-3B:

[0214] (1) The binding activity of ADI-56249-G1LALA, ADI-56145-G1LALA, ADI-56204-G1, ADI-56204-G1LALA, ADI-56127-G1, and ADI-56127-G1LALA to human PVRIG protein overexpressed on the surface of CHO cells was superior to that of the control molecules Mab46-G1, Mab46-G1LALA, and COM701-G4;

[0215] (2) The binding activity of ADI-56249-G1LALA, ADI-56204-G1, ADI-56204-G1LALA, ADI-56127-G1, and ADI-56127-G1LALA to cynomolgus monkey PVRIG protein overexpressed on the surface of CHO cells was superior to that of the control molecules Mab46-G1, Mab46-G1LALA, and COM701-G4;

[0216] (3) ADI-56127-G1 and ADI-56127-G1LALA showed significant binding to mouse PVRIG protein overexpressed on the surface of CHO cells, and the binding activity was comparable to that of the control molecules Mab46-G1 and Mab46-G1LALA.

[0217] The following conclusions can be drawn from Table 2 and Figures 4A to 4B and 5A to 5B:

[0218] (1) The activities of ADI-56145-G1LALA, ADI-56204-G1, ADI-56204-G1LALA, ADI-56127-G1, and ADI-56127-G1LALA in blocking the binding of human PVRIG to human CD112 protein overexpressed on the surface of CHO cells were comparable to those of the control molecules Mab46-G1, Mab46-G1LALA, and COM701-G4;

[0219] (2) Some anti-PVRIG antibody molecules (ADI-56127-G1 and ADI-56127-G1LALA) that bind to mouse PVRIG protein overexpressed on the surface of CHO cells can significantly block the binding of mouse PVRIG to mouse CD112 protein, and the blocking activity is better than that of the control molecules Mab46-G1 and Mab46-G1LALA.

[0220] Example 4: Anti-PVRIG Antibody Binds to PVRIG on the Surface of Primary T Cells

[0221] The binding activity of the anti-PVRIG antibody of the invention to PVRIG on the surface of activated T cells was detected based on flow cytometry.

[0222] Specifically, human PBMCs were sorted according to the protocol provided by STEMCELL (stemcell, catalog number: #17951C) to obtain human total T cells. The T cell concentration was adjusted to 1.0×10 6cells / mL, 1 μL of IL-2 stock solution (1 million IU) was added, and CD3 / CD28 Dynabeads (Gibco, Cat. No. 11132D) were added at a 1:1 ratio (bead-to-cell ratio). The cells were cultured at 37°C in a 5% CO2 incubator for 48 hours. Activated T cells were adjusted to an appropriate cell density and added to a 96-well flow cytometer. After centrifugation, serially diluted samples were added and incubated at 4°C for 30 minutes. The cells were washed twice with PBS, and fluorescent secondary antibodies were added at appropriate concentrations. The cells were incubated at 4°C for 30 minutes, and then washed twice with PBS. The cells were resuspended in PBS, analyzed on a CytoFlex flow cytometer, and the corresponding MFI was calculated.

[0223] The results are shown in Figure 6. The results show that the anti-PVRIG antibodies ADI-56127-G1 and ADI-56127-G1LALA of the present invention can bind to PVRIG molecules on the surface of activated T cells, and the binding activity is better than that of the control molecules Mab46-G1, Mab46-G1LALA, and COM701-G4.

[0224] Example 5: Luciferase reporter gene system detection of the combined blocking effect of anti-PVRIG antibody and anti-TIGIT antibody

[0225] To detect the combined blocking activity of anti-PVRIG antibodies and anti-TIGIT antibodies at the cellular level, the following luciferase reporter gene system was constructed in this example. Briefly described, cells were transfected with lentivirus to construct a CHO-K1 cell line (CHO-K1-CD155-CD112) overexpressing human CD155, human CD112, and OKT-3scFv, and a Jurkat cell line (Jurkat-TIGIT-PVRIG-luc) overexpressing human TIGIT, human PVRIG, and NF-AT luciferase reporter genes. This reporter gene system was subsequently used to carry out relevant experiments.

[0226] Specifically, digest to obtain CHO-K1-CD155-CD112 functional cells, adjust the cell density, add 100 μL / well to a 96-well white-bottom plate, and culture overnight. The next day, prepare a Jurkat-TIGIT-PVRIG-luc effector cell suspension, and dilute the sample to be tested with a gradient of reaction culture medium. Take out the white-bottom plate, aspirate the culture supernatant, add 40 μL / well of the diluted sample to the white-bottom plate, and at the same time, add 40 μL / well of the Jurkat-TIGIT-PVRIG-luc effector cell suspension and culture at 37°C, 5% CO2 incubator for 6 hours. After the culture is completed, add Bio-Glo TM Reagent, and use a multifunctional microplate reader to read the fluorescence signal value.

[0227] The results are shown in Figure 7. The results showed that the anti-PVRIG antibodies ADI-56127-G1LALA, ADI-56145-G1LALA, ADI-56204-G1LALA, and ADI-56249-G1LALA of the present invention, respectively, in a molar ratio of 1:1, combined with the anti-TIGIT antibody Tiragolumab, were able to eliminate the CD112-mediated PVRIG downstream inhibitory signaling pathway and the CD155-mediated TIGIT downstream inhibitory signaling pathway, and greatly enhanced the expression of the reporter gene luciferase, and the activity was comparable to that of the control molecule COM701-G4.

[0228] Example 6: Luciferase reporter gene system detection of the combined blocking effect of anti-PVRIG antibody and anti-TIGIT and anti-PD-L1 antibodies

[0229] To detect the combined blocking activity of anti-PVRIG antibodies with anti-TIGIT and anti-PD-L1 antibodies at the cellular level, the following luciferase reporter gene system was constructed in this example. Briefly described as follows: based on Example 5, CHO-K1-CD155-CD112 was lentivirally infected to overexpress PD-L1 to obtain CHO-K1-CD155-CD112-PD-L1 functional cells, and Jurkat-TIGIT-PVRIG-luc was lentivirally infected to overexpress PD-1 to obtain Jurkat-TIGIT-PVRIG-PD-1-luc effector cell suspension. This reporter gene system was subsequently used to carry out relevant experiments.

[0230] Specifically, CHO-K1-CD155-CD112-PD-L1 functional cells were obtained by digestion, the cell density was adjusted, 100 μL / well was added to a 96-well white bottom plate, and cultured overnight. The next day, a Jurkat-TIGIT-PVRIG-PD-1-luc effector cell suspension was prepared, and the sample to be tested was gradiently diluted with the reaction medium. The white bottom plate was removed, the culture supernatant was aspirated, 40 μL / well of the diluted sample was added to the white bottom plate, and 40 μL / well of the Jurkat-TIGIT-PVRIG-PD-1-luc effector cell suspension was added at the same time, and the plate was placed at 37°C, 5% CO2 incubator for 6 hours. After the culture is completed, 80 μL / well of Bio-Glo was added. TM Reagent, and use a multifunctional microplate reader to read the fluorescence signal value.

[0231] The results are shown in Figure 8. The results showed that the anti-PVRIG antibodies ADI-56127-G1LALA, ADI-56145-G1LALA, ADI-56204-G1LALA, and ADI-56249-G1LALA of the present invention, respectively, in combination with the anti-TIGIT antibody Tiragolumab and the anti-PD-L1 antibody Atezolizumab (ATE) at a molar ratio of 1:1:1, were able to further enhance the reporter gene luciferase expression by blocking the downstream inhibitory signals mediated by PVRIG / CD112, TIGIT / CD155, and PD-1 / PD-L1, respectively, and the activity was comparable to that of the control molecule COM701-G4.

[0232] Example 7: In vitro ADCC activity detection of anti-PVRIG antibodies

[0233] The in vitro ADCC activity of the invented anti-PVRIG antibody was detected based on the luciferase reporter gene system.

[0234] Specifically, Jurkat-NFAT-Luciferase-CD16 ADCC effector cells (purchased from Promega) were expanded and resuspended to 4×10 cells in 1640 medium containing 10% low IgG FBS. 6 Resuspend CHO-huPVRIG cells, CHO-cynoPVRIG cells, and CHO-muPVRIG cells in 1640 medium containing 10% low IgG FBS to a dilution of 1.6×10 cells / mL. 6 cells / mL. Mix the three cell suspensions described above with Jurkat-NF-AT-Luciferase-CD16 cells at a 1:1 ratio, and add 50 μL / well to a sterile 96-well white-bottom plate. Add serial dilutions of the antibody sample to be tested in 1640 medium supplemented with 10% low-IgG FBS. Incubate at 37°C, 5% CO2 for 6 hours. After incubation, remove the cells, equilibrate at room temperature for 5 minutes, and add 100 μL / well of Bio-Glo™ reagent. Read the fluorescence signal using a multi-function microplate reader.

[0235] The results are shown in Figures 9A to 9C. The results demonstrate that the anti-PVRIG antibodies ADI-56204-G1 and ADI-56127-G1 of the present invention can mediate ADCC activity against CHO-huPVRIG cells, CHO-cynoPVRIG cells, and CHO-muPVRIG cells in vitro using a luciferase reporter gene system. Furthermore, the ADCC activity mediated by ADI-56204-G1 against CHO-huPVRIG cells and CHO-cynoPVRIG cells is stronger than that of the control molecule Mab46-G1. The ADCC activity mediated by ADI-56127-G1 against CHO-huPVRIG cells, CHO-cynoPVRIG cells, and CHO-muPVRIG cells is comparable to that of the control molecule Mab46-G1.

[0236] Example 8: Pharmacodynamic study of anti-PVRIG antibodies in wild-type Balb / c mice

[0237] In this experiment, CT-26 mouse colon cancer cells (purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.) were inoculated into wild-type Balb / c mice to determine the anti-tumor effect of the anti-PVRIG antibody of the present invention.

[0238] Specifically, CT-26 cell suspension was prepared first, and 0.1 mL (approximately 5 × 10 5 The CT-26 tumor-bearing mouse model was established with cells. When the average tumor volume grew to about 100 mm 3 Mice were divided into groups and treated with different doses of PBS or antibodies using the same volume of intraperitoneal injection. Each group consisted of six mice. Tumor volume and body weight were monitored every two to three days for two to three weeks. The dosage and method of administration are shown in Table 3.

[0239] Table 3: Anti-PVRIG Antibody Tumor Inhibitory Activity Assay

[0240] The results are shown in Figure 10. The results showed that the anti-PVRIG antibody ADI-56127-G1 of the present invention can significantly inhibit the growth of CT26 tumors in mice.

[0241] Example 9: In vivo pharmacodynamic study of anti-PVRIG antibodies in NDG mice co-inoculated with A375 and human PBMC

[0242] This study examined the anti-tumor effects of the anti-PVRIG antibodies of the present invention in a model in which B-NDG mice were co-inoculated with A375 (purchased from Addexbio, C0020004, a human malignant melanoma cell line) and human PBMC (Shanghai Miaoshun, A10S033014 / PB100C) (A375huPBMC model). Human immune cells (PBMCs) were inoculated into immunodeficient mice to generate a humanized tumor mouse model with partial reconstitution of the human immune system.

[0243] Specifically, A375 cells and human PBMC were mixed in equal volumes at a ratio of 1:1 to form a 0.1 mL cell suspension, which was then injected subcutaneously into the right ventral groove of mice to establish the A375huPBMC model. 3 Around 6:00 p.m., mice were divided into groups and given intraperitoneal injections of different doses of PBS or antibody at the same volume, with six mice per group. Tumor volume and body weight were monitored every 2-3 days for 2 to 3 weeks. Dosage and administration methods are shown in Table 4.

[0244] Table 4: Dosing regimen for anti-PVRIG antibody A375 PBMC model

[0245] The results are shown in Figure 11. The results show that the anti-PVRIG antibody ADI-56127-G1 of the present invention can significantly inhibit the growth of mouse A375 tumors, and its anti-tumor activity is better than that of the control molecules Mab46-G1 and COM701-G4.

[0246] Example 10: In vivo pharmacodynamic study of anti-PVRIG antibody combined with anti-TIGIT antibody in NDG mice inoculated with A375 and human PBMC

[0247] In this experiment, A375 and human PBMC tumor-bearing mouse models were established by subcutaneous mixed inoculation (the modeling steps were the same as those in Example 9). 3 Around 6:00 p.m., mice were divided into groups and given intraperitoneal injections of different doses of PBS or antibody at the same volume, with six mice per group. Tumor volume and body weight were monitored every 2-3 days for 2 to 3 weeks. Dosage and administration methods are shown in Table 5.

[0248] Table 5: Dosing regimens for anti-PVRIG antibody and anti-TIGIT antibody A375 models

[0249] The results are shown in Figure 12. The results showed that the combined administration of the anti-PVRIG antibody ADI-56127-G1 of the present invention and the anti-TIGIT monoclonal antibody had a more significant tumor inhibitory effect than the treatment with either drug alone.

[0250] The sequence of the anti-TIGIT monoclonal antibody used in this example is as follows:

[0251] Anti-TIGIT antibody VH amino acid sequence:

[0252] Anti-TIGIT antibody VL amino acid sequence:

[0253] The CDRs of the above-mentioned anti-TIGIT antibody are as follows:

[0254] HCDR1:GSISSYDHYWT(SEQ ID NO:42)

[0255] HCDR2:TVYYSGSTFHNPSLKS(SEQ ID NO:43)

[0256] HCDR3:ARVGPDVSHPPFDY(SEQ ID NO:44)

[0257] LCDR1:RASQSISSYLN(SEQ ID NO:45)

[0258] LCDR2: AASSLQS (SEQ ID NO: 46)

[0259] LCDR3:QQSYSTPIT(SEQ ID NO:47)

[0260] The anti-TIGIT monoclonal antibody heavy chain constant region used in this example adopts the wild-type human IgG1 heavy chain constant region (SEQ ID NO: 33).

[0261] The anti-TIGIT monoclonal antibody light chain constant region used in this example adopts the human kappa light chain constant region (SEQ ID NO: 36).

[0262] Example 11: In vivo pharmacodynamic study of anti-PVRIG antibody combined with anti-PD-1 and anti-TIGIT antibodies in NDG mice inoculated with A375 and human PBMCs

[0263] In this experiment, A375 and human PBMC tumor-bearing mouse models were first established by subcutaneous mixed inoculation (the modeling steps were the same as those in Example 9). 3 Around 6:00 p.m., mice were divided into groups and given different doses of PBS or antibody treatment by intraperitoneal injection at the same volume. Tumor volume and body weight changes were monitored every 2-3 days for 2 to 3 weeks. Dosage and administration methods are shown in Table 6.

[0264] Table 6: Dosing regimens for anti-PVRIG antibody, anti-PD-1, and anti-TIGIT antibody A375 models

[0265] The results are shown in FIG13 , which indicate that the combined administration of the anti-PVRIG antibody ADI-56127-G1, anti-TIGIT monoclonal antibody, and anti-PD-1 antibody of the present invention can effectively inhibit tumor growth, and the tumor inhibitory activity on A375 is significantly better than that of other dosing groups.

[0266] The sequence of the anti-TIGIT monoclonal antibody used in this example is consistent with that in Example 10.

[0267] The sequence of the anti-PD-1 monoclonal antibody used in this example is as follows:

[0268] Anti-PD-1 antibody VH amino acid sequence

[0269] Anti-PD-1 antibody VL amino acid sequence

[0270] The six CDRs of the above-mentioned anti-PD-1 antibody are as follows:

[0271] HCDR1:YTFTEYYIY(SEQ ID NO:50)

[0272] HCDR2:GINPSNGGTNFNEKFKP(SEQ ID NO:51)

[0273] HCDR3:TVRDFRFDKGFKY(SEQ ID NO:52)

[0274] LCDR1:RASKSVSTSGLNYVH(SEQ ID NO:53)

[0275] LCDR2:LGSYLDS (SEQ ID NO:54)

[0276] LCDR3: QQSWELPLT(SEQ ID NO:55)

[0277] The heavy chain constant region of the anti-PD-1 monoclonal antibody used in this example adopts the IgG1 heavy chain constant region modified by L234A and L235A (SEQ ID NO: 34)

[0278] The anti-PD-1 monoclonal antibody light chain constant region used in this example adopts the human kappa light chain constant region (SEQ ID NO: 36)

[0279] Example 12: Study on the half-life of anti-PVRIG antibodies in mice

[0280] The half-life of the anti-PVRIG antibody ADI-56127-G1 of the present invention in mice was detected by a single tail vein injection method.

[0281] Specifically, the experiment used Balb / c mice, 3 males and 3 females, under a 12 / 12 hour light / dark cycle, at a temperature of 24°C ± 2°C, a humidity of 40%-70%, and free access to water and food. On the day of the experiment, the Balb / c mice were injected with a single tail vein injection of monoclonal antibody molecules at a dose of 10 mg / kg. Blood was collected from the mouse eye sockets at 5 minutes, 0.5 hours, 2 hours, 6 hours, 24 hours, 48 ​​hours, 96 hours, 168 hours, 336 hours, and 504 hours after administration. Whole blood samples were placed at 2°C-8°C for 30 minutes, centrifuged at 12,000 rpm for 5 minutes, and serum was collected. The resulting serum was then centrifuged at 12,000 rpm for 5 minutes at 2°C-8°C and stored at -80°C. The content of monoclonal antibody molecules in the serum was detected by ELISA.

[0282] The results are shown in Figure 14. The results showed that the half-life of the anti-PVRIG antibody ADI-56127-G1 of the present invention in mice after a single injection was 160 hours.

[0283] Although specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and substitutions may be made to those details in light of all the teachings disclosed herein, and such modifications are within the scope of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof.

Claims

1. An anti-PVRIG antibody or an antigen-binding fragment thereof, wherein: The antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein: the heavy chain variable region of the antibody, The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 10, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 11, The amino acid sequence of HCDR1 is shown in SEQ ID NO: 15, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 16, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 17, The amino acid sequence of HCDR1 is shown in SEQ ID NO: 21, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 22, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 23, or The amino acid sequence of HCDR1 is shown in SEQ ID NO: 27, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 28, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 29; and the light chain variable region of the antibody, The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 13, and the amino acid sequence of LCDR1 is shown in SEQ ID NO: 14, The amino acid sequence of LCDR1 is shown in SEQ ID NO: 18, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 19, and the amino acid sequence of LCDR1 is shown in SEQ ID NO: 20, The amino acid sequence of LCDR1 is shown in SEQ ID NO: 24, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 25, and the amino acid sequence of LCDR1 is shown in SEQ ID NO: 26, or The amino acid sequence of LCDR1 is shown in SEQ ID NO:30, the amino acid sequence of LCDR1 is shown in SEQ ID NO:31, and the amino acid sequence of LCDR1 is shown in SEQ ID NO:

32.

2. The anti-PVRIG antibody or antigen-binding fragment thereof according to claim 1, wherein The amino acid sequence of HCDR1 is shown in SEQ ID NO:9, the amino acid sequence of HCDR2 is shown in SEQ ID NO:10, the amino acid sequence of HCDR3 is shown in SEQ ID NO:11, the amino acid sequence of LCDR1 is shown in SEQ ID NO:12, the amino acid sequence of LCDR2 is shown in SEQ ID NO:13, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:14; The amino acid sequence of HCDR1 is shown in SEQ ID NO: 15, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 16, the amino acid sequence of HCDR3 is shown in SEQ ID NO: 17, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 18, the amino acid sequence of LCDR2 is shown in SEQ ID NO: 19, and the amino acid sequence of LCDR3 is shown in SEQ ID NO: 20; The amino acid sequence of HCDR1 is shown in SEQ ID NO:21, the amino acid sequence of HCDR2 is shown in SEQ ID NO:22, the amino acid sequence of HCDR3 is shown in SEQ ID NO:23, the amino acid sequence of LCDR1 is shown in SEQ ID NO:24, the amino acid sequence of LCDR2 is shown in SEQ ID NO:25, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:26; or The amino acid sequence of HCDR1 is shown in SEQ ID NO:27, the amino acid sequence of HCDR2 is shown in SEQ ID NO:28, the amino acid sequence of HCDR3 is shown in SEQ ID NO:29, the amino acid sequence of LCDR1 is shown in SEQ ID NO:30, the amino acid sequence of LCDR2 is shown in SEQ ID NO:31, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:

32.

3. The anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 2, wherein: The amino acid sequence of the heavy chain variable region is selected from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7; and The amino acid sequence of the light chain variable region is selected from SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO:

8.

4. The anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 2; The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 3, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 4; The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 5, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 6; or The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

8.

5. The anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein The heavy chain constant region of the antibody is Ig gamma-1 chain C region or Ig gamma-4 chain C region; the light chain constant region is Ig kappa chain C region; Preferably, the amino acid sequence of the heavy chain constant region of the antibody is shown as SEQ ID NO: 33, SEQ ID NO: 34 or SEQ ID NO: 35, and the amino acid sequence of the light chain constant region of the antibody is shown as SEQ ID NO:

36.

6. The anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein According to the EU numbering system, the heavy chain constant region of the antibody comprises a L234A mutation and a L235A mutation.

7. The anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein The anti-PVRIG antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single-chain antibody, humanized antibody, chimeric antibody or diabody.

8. The anti-TIGIT antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, wherein The antibodies include non-CDR regions, and the non-CDR regions are from a species other than murine, such as a human antibody.

9. The anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, wherein EC binding of the antibody to human PVRIG protein overexpressed on the surface of CHO cells 50 Less than 3 nM, less than 2.9 nM or less than 2.8 nM; preferably, the EC 50 Measured by flow cytometry.

10. An isolated nucleic acid molecule encoding the anti-TIGIT antibody or antigen-binding fragment thereof according to any one of claims 1 to 9. A recombinant vector comprising the isolated nucleic acid molecule of claim 10 .

12. A host cell comprising the isolated nucleic acid molecule of claim 10 or the recombinant vector of claim 11.

13. A conjugate comprising an antibody and a conjugated moiety, wherein: The antibody is the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, and the coupling moiety is a detectable label; preferably, the coupling moiety is a radioisotope, a fluorescent substance, a colored substance or an enzyme.

14. A kit comprising the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or the conjugate according to claim 13; Preferably, the kit further comprises a second antibody that specifically recognizes the antibody; optionally, the second antibody further comprises a detectable label, such as a radioisotope, a fluorescent substance, a colored substance or an enzyme.

15. A pharmaceutical composition comprising the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 or the conjugate according to claim 13; optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

16. The pharmaceutical composition according to claim 15, further comprising one or more anti-TIGIT antibodies; Preferably, the pharmaceutical composition further comprises one or more anti-PD-1 antibodies or one or more anti-PD-L1 antibodies.

17. The pharmaceutical composition according to any one of claims 15 to 16, wherein The molar ratio of the anti-PVRIG antibody or its antigen-binding fragment to the anti-TIGIT antibody is (1:5)-(5:1); and / or The molar ratio of the anti-PVRIG antibody or its antigen-binding fragment to the anti-PD-1 antibody or anti-PD-L1 antibody is (1:5)-(5:1); 18. The pharmaceutical composition according to any one of claims 16 to 17, wherein The anti-TIGIT antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein: The amino acid sequence of HCDR1 is shown in SEQ ID NO: 42, and the amino acid sequence of HCDR2 is shown in SEQ ID NO: 43, the amino acid sequence of HCDR3 is shown in SEQ ID NO: 44, the amino acid sequence of LCDR1 is shown in SEQ ID NO: 45, the amino acid sequence of LCDR2 is shown in SEQ ID NO: 46, and the amino acid sequence of LCDR3 is shown in SEQ ID NO: 47; Preferably, the amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO:40, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

41.

19. The pharmaceutical composition according to any one of claims 16 to 18, wherein The anti-PD-1 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein: The amino acid sequence of HCDR1 is shown in SEQ ID NO:50, the amino acid sequence of HCDR2 is shown in SEQ ID NO:51, the amino acid sequence of HCDR3 is shown in SEQ ID NO:52, the amino acid sequence of LCDR1 is shown in SEQ ID NO:53, the amino acid sequence of LCDR2 is shown in SEQ ID NO:54, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:55; Preferably, the amino acid sequence of the heavy chain variable region of the anti-PD-1 antibody is shown in SEQ ID NO: 48, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

49.

20. A combination product comprising a first product and a second product in separate packages, wherein: The first product comprises the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 or the conjugate according to claim 13; The second product comprises at least one anti-TIGIT antibody; Preferably, the combination product further comprises a third product comprising at least one anti-PD-1 antibody or at least one anti-PD-L1 antibody; Preferably, the first product, the second product and the third product further independently contain one or more pharmaceutically acceptable excipients; Preferably, the combination product further comprises product instructions.

21. The combination product according to claim 20, wherein The molar ratio of the anti-PVRIG antibody or its antigen-binding fragment to the anti-TIGIT antibody is (1:5)-(5:1); and / or The molar ratio of the anti-PVRIG antibody or its antigen-binding fragment to the anti-PD-1 antibody or anti-PD-L1 antibody is (1: 5)-(5:1)。 22. A combination product according to any one of claims 20 to 21, wherein The anti-TIGIT antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein: The amino acid sequence of HCDR1 is shown in SEQ ID NO:42, the amino acid sequence of HCDR2 is shown in SEQ ID NO:43, the amino acid sequence of HCDR3 is shown in SEQ ID NO:44, the amino acid sequence of LCDR1 is shown in SEQ ID NO:45, the amino acid sequence of LCDR2 is shown in SEQ ID NO:46, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:47; Preferably, the amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO:40, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

41.

23. A combination product according to any one of claims 20 to 22, wherein The anti-PD-1 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein: The amino acid sequence of HCDR1 is shown in SEQ ID NO:50, the amino acid sequence of HCDR2 is shown in SEQ ID NO:51, the amino acid sequence of HCDR3 is shown in SEQ ID NO:52, the amino acid sequence of LCDR1 is shown in SEQ ID NO:53, the amino acid sequence of LCDR2 is shown in SEQ ID NO:54, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:55; Preferably, the amino acid sequence of the heavy chain variable region of the anti-PD-1 antibody is shown in SEQ ID NO: 48, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

49.

24. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 or the conjugate according to claim 13 in the preparation of a medicament for treating or preventing tumors; Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer; Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.

25. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or the conjugate according to claim 13, for use in treating or preventing tumors; Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer; Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.

26. A method for treating or preventing tumors, comprising the step of administering to a subject in need thereof an effective amount of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 or the conjugate according to claim 13; Preferably, the tumor is selected from one or more of colon cancer, melanoma, lung cancer, kidney cancer, endometrial cancer, breast cancer, skin cancer, ovarian cancer, gastric cancer, head and neck cancer, liver cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, rectal cancer, pancreatic cancer, cervical tumor, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, prostate cancer and testicular cancer; Preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer.

Citation Information

Cited By

  • Pvrig binding molecule and use thereof

    WO2026109009A1